Novel therapeutic targets in rheumatoid arthritis

被引：188

作者：

Koenders, Marije I. ^{[1
]}

van den Berg, Wim B. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Expt Rheumatol, NL-6525 ED Nijmegen, Netherlands

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2015年 / 36卷 / 04期

关键词：

rheumatoid arthritis; therapeutic targets; JAK; Th17; IL-17; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; MODIFYING ANTIRHEUMATIC DRUGS; DOUBLE-BLIND; PHASE-II; T-CELLS; INADEQUATE RESPONSE; TH17; CELLS; EULAR RECOMMENDATIONS; PSORIATIC-ARTHRITIS; JOINT INFLAMMATION;

D O I：

10.1016/j.tips.2015.02.001

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.

引用

页码：189 / 195

页数：7

共 78 条

[1]

Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis [J].

Abdollahi-Roodsaz, Shahla ;

Joosten, Leo A. B. ;

Koenders, Marije I. ;

Devesa, Isabel ;

Roelofs, Mieke F. ;

Radstake, Timothy R. D. J. ;

Heuvelmans-Jacobs, Marleen ;

Akira, Shizuo ;

Nicklin, Martin J. H. ;

Ribeiro-Dias, Fatima ;

Van den Berg, Wim B. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :205-216

[2]

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway [J].

Alzabin, Saba ;

Abraham, Sonya M. ;

Taher, Taher E. ;

Palfreeman, Andrew ;

Hull, Dobrina ;

McNamee, Kay ;

Jawad, Ali ;

Pathan, Ejaz ;

Kinderlerer, Anne ;

Taylor, Peter C. ;

Williams, Richard ;

Mageed, Rizgar .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (10) :1741-1748

[3]

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].

Baeten, Dominique ;

Baraliakos, Xenofon ;

Braun, Juergen ;

Sieper, Joachim ;

Emery, Paul ;

van der Heijde, Desiree ;

McInnes, Iain ;

van Laar, Jacob M. ;

Landewe, Robert ;

Wordsworth, Paul ;

Wollenhaupt, Juergen ;

Kellner, Herbert ;

Paramarta, Jacqueline ;

Wei, Jiawei ;

Brachat, Arndt ;

Bek, Stephan ;

Laurent, Didier ;

Li, Yali ;

Wang, Ying A. ;

Bertolino, Arthur P. ;

Gsteiger, Sandro ;

Wright, Andrew M. ;

Hueber, Wolfgang .

LANCET, 2013, 382 (9906) :1705-1713

[4]

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].

Bettelli, E ;

Carrier, YJ ;

Gao, WD ;

Korn, T ;

Strom, TB ;

Oukka, M ;

Weiner, HL ;

Kuchroo, VK .

NATURE, 2006, 441 (7090) :235-238

[5]

Boyle D.L., 2014, ANN RHEUM DIS

[6]

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis [J].

Burmester, Gerd R. ;

Weinblatt, Michael E. ;

McInnes, Iain B. ;

Porter, Duncan ;

Barbarash, Olga ;

Vatutin, Mykola ;

Szombati, Istvan ;

Esfandiari, Ehsanollah ;

Sleeman, Matthew A. ;

Kane, Christopher D. ;

Cavet, Guy ;

Wang, Bing ;

Godwood, Alex ;

Magrini, Fabio .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) :1445-1452

[7]

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].

Burmester, Gerd R. ;

Blanco, Ricardo ;

Charles-Schoeman, Christina ;

Wollenhaupt, Juergen ;

Zerbini, Cristiano ;

Benda, Birgitta ;

Gruben, David ;

Wallenstein, Gene ;

Krishnaswami, Sriram ;

Zwillich, Samuel H. ;

Koncz, Tamas ;

Soma, Koshika ;

Bradley, John ;

Mebus, Charles .

LANCET, 2013, 381 (9865) :451-460

[8]

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy [J].

Chen, Der-Yuan ;

Chen, Yi-Ming ;

Chen, Hsin-Hua ;

Hsieh, Chia-Wei ;

Lin, Chi-Chen ;

Lan, Joung-Liang .

ARTHRITIS RESEARCH & THERAPY, 2011, 13 (04)

[9]

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation [J].

Codarri, Laura ;

Gyuelveszi, Gabor ;

Tosevski, Vinko ;

Hesske, Lysann ;

Fontana, Adriano ;

Magnenat, Laurent ;

Suter, Tobias ;

Becher, Burkhard .

NATURE IMMUNOLOGY, 2011, 12 (06) :560-U248

[10]

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis [J].

Cohen, Stanley ;

Radominski, Sebastiao C. ;

Gomez-Reino, Juan J. ;

Wang, Lisy ;

Krishnaswami, Sriram ;

Wood, Susan P. ;

Soma, Koshika ;

Nduaka, Chudi I. ;

Kwok, Kenneth ;

Valdez, Hernan ;

Benda, Birgitta ;

Riese, Richard .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (11) :2924-2937

← 1 2 3 4 5 6 7 8 →